Research Article
Report from a Survey of Parents Regarding the Use of Cannabidiol (Medicinal cannabis) in Mexican Children with Refractory Epilepsy
Table 1
General characteristics of 43 Mexican children with RE receiving treatment with CBD.
| | | Surveys | #/43 (100%) |
| | Age | Minimum 9.5 months | Average: 7.6 yrs ± 4.3 | | Maximum 18 years |
| | Sex | Male | 27 (62.7%) | | Female | 16 (37.2%) |
| | Evolution | <2 years | 8 (18.6%) | | 2–6 years | 16 (37.2%) | | 6–10 years | 11 (25.5%) | | >10 years | 8 (18.6%) |
| | Diagnoses | Lennox-Gastaut S. | 20 (47%) | | West S. | 8 (19%) | | Doose S. | 1 (2%) | | Ohtahara S. | 1 (2%) | | Unspecific R.E. | 13 (30%) |
| | # antiepileptic drugs before CBD | 1-2 | 3 (7.5%) | | 3-4 | 25 (62.5%) | | 5-6 | 11 (27.5%) | | 7–10 | 2 (5.0%) | | >10 | 0 (0.0%) |
| | # antiepileptic drugs After CBD | 1-2 | 14 (32.5%) | | 3-4 | 24 (55.8%) | | 5-6 | 4 (9.3%) | | 7–10 | 0 (0.0%) | | >10 | 1 (2.3%) |
| | CBD product | CBD 5000 mg | 31 (72%) | | CBD 1000 mg | 2 (4.6%) | | CBD + THC 5000 mg | 3 (6.9%) | | CBD + THC 500 mg | 2 (4.6%) | | Other CBD/THC | 5 (11.6%) |
| | CBD dose mg/kg/day | <1 | 3 (6.9%) | | 1–3.9 | 27 (55.2%) | | 4–6.9 | 5 (19.4%) | | 7–8.9 | 3 (6.9%) | | 9–11 | 0 (0.0%) | | Unknown | 5 (11.6%) |
| | CBD treatment time in months | <1 | 4 (9.3%) | | 1-2 | 7 (16.2%) | | 2-3 | 7 (16.2%) | | 3-4 | 12 (27.9%) | | 5-6 | 7 (16.2%) | | 6–12 | 6 (13.9%) | | >12 | 0 (0%) |
|
|
